Scancell Share Discussion Threads

[golcheja] 05/6/2023 09:12

Breaking news SC attending, that is bizarre 1000s of companies attending and that is so important because SC didn’t attend last year, that walks.
Nobel price
Encouraging
Next RNS mind blowing
Shout to the world
And the rest of the buzz words
Bottom line as big mamma says, commercialisation talks and buzz buzz word walks.

[marcusl2] 05/6/2023 08:57

BIO International Convention
June 5-8, 2023

looks like Scancell are attending Bio 2023 in Boston next week - apparently the World's largest biotech/pharma partnering event.


HTTPS://www.bio.org/events/bio-international-convention


Berm

[golcheja] 05/6/2023 08:44

This PR can also be a storm in a teacup SC may be good on the science , but equally as good they are on science the bad they are on anything else.

[markingtime] 05/6/2023 07:18

So would expect some news Weds/Thurs this week........the new specialist PR firm is another straw in the wind indicating some important news coming soon.

[marcusl2] 04/6/2023 13:56

Modi-2 still to come.

The vaccine was very effective (90% survival) as the induced CD4 T cells directly targeted the homocitrullinated tumor and likely reversed the immunosuppressive environment.

Conclusion We propose that MPO, potentially produced by MDSCs, catalyzes the buildup of cyanate in the TME which diffuses into tumor cells causing homocitrullination of cytoplasmic proteins which are degraded and, in the presence of IFNγ, presented by MHC-II for direct CD4 T-cell recognition. Homocitrullinated proteins are a new target for cancer vaccines and may be particularly effective against tumors containing high levels of MPO expressing MDSCs.

HTTPS://jitc.bmj.com/content/9/7/e001910

The Company expects that the combination of Scancell’s Modi-2 with a highly effective platform for inducing T cells (Vaccitech’s SNAPvax™ technology) will lead to a potentially superior therapeutic vaccine candidate

Combining this technology with our expertise will allow us to develop a rapid manufacturing process for Modi-2, with the hope that we can bring it into a Phase 1 clinical study during 2024

HTTPS://calculuscapital.com/scancell-in-licenses-vaccitech-technology-advancing-modi-2-towards-the-clinic/

[marcusl2] 03/6/2023 21:42

We just have to wait for an update on the patients now.

The poster data from early Feb
13 evaluable patients, the best overall response
by RECIST v1.1 included 1 PR (SCCHN), 6 SD and 6
PD

Trinty 21st Feb

1 PR , 7 SD

I am expecting further improvement. In animals Modi took time to work its magic.

We can now also look forward to Cohort 4, high dose Modi-1 plus CPI (first patient treated others being screened.

[miavoce] 03/6/2023 20:29

Poster published:-

hTTps://www.scancell.co.uk/Data/Sites/1/media/publications/posters/asco_modify-study-poster_april_final-2.0x.pdf

[golcheja] 03/6/2023 19:49

Same poster in two major conferences. That implicitly saying that modi-1 works, otherwise why bother sending folks again with all expenses if trial is deem to fail?
Cohort3 is in progress and cohort4 patient got injected, no safety issues and green light was given , add that ti the poster although back dated to Feb… it provide a strong hint that the platform can handle the disease it was initially designed for.

[small crow] 03/6/2023 16:29

Seems we can't look at the poster until after the entire conference ie after 6th June?

[marcusl2] 03/6/2023 14:04

Session date and 08:00 AM - 11:00 AM CDT, June 3, 2023
time

GMT 2pm - 5pm

Abstract 2566
Poster Board number 408

HTTPS://www.voxmarkets.co.uk/rns/announcement/d001978a-b84f-4f6f-a21a-0ba590489ba9/

[marcusl2] 03/6/2023 10:30

Vox

Scancell moves closer to commercialising cancer immunotherapy treatment

HTTPS://www.voxmarkets.co.uk/articles/scancell-moves-closer-to-commercialising-cancer-immunotherapy-treatment--36e46fb/

[marcusl2] 03/6/2023 10:29

Trinity

21 February 2023

Moditope shows early signs of efficacy The Phase I/II Modi-1 study (ModiFY) is a two stage trial. The initial dose escalation and safety phase is followed by a number of specific patient cohorts that explore for signs of efficacy in triple negative breast cancer (TNBC), ovarian cancer, head & neck cancer, and renal cancer as both Modi-1 monotherapy and in combination with checkpoint inhibitors (CPI). A total of up to 138 patients across up to 20 UK sites will be treated, with 23 successfully vaccinated so far. Of these, 14 patients have reached the eight-week evaluation point, with no dose-limiting toxicities or safety concerns seen. Despite having failed at least one round of prior treatment and having progressive disease prior to study enrolment, one patient has a confirmed partial response and seven have stable disease.

Progressing into combination therapy With safety and tolerability confirmed, Modi-1 is progressing into further dose escalation as monotherapy and, importantly, initiating combination therapy with a CPI. It is data from these elements of the study that will provide multiple insights into how and where Modi-1 could be employed. The indications selected are all aggressive and difficult to treat cancers, with clear clinical needs. If the early efficacy signals seen in the first part of ModiFY are confirmed in the latter parts, this would effectively demonstrate Moditope’s mode of action and would further de-risk the programme in our rNPV model.

Raising our valuation to £300.1m, equivalent to 36.7p We explored Scancell’s investment case in detail in our recent February 2023 Outlook. Increasing the probability on Moditope to 12.5% (from 10%) sees our rNPV rise to £300.1m (from £269.6m), or 36.7p/share (30.5p fully diluted). The next 12 to 18 months should see several potential value inflection points, ranging from trial results to further commercial deals. Positive outcomes should boost investor sentiment materially.

HTTPS://www.trinitydelta.org/research-notes/modi-1-successful-in-first-part-of-phase-i-ii-trial/

[panama7] 03/6/2023 08:38

Since Moditope went into trial 6 months ago has the share price increased exponentially ? It's just I seem to remember when Scib was in trial it went up ten fold in 6 months. After all isn't Moditope " The Serendipitous Discovery " and isn't Moditope the platform that the whole of Big Pharma were supposed to be interested in. In other news Pfizer power ahead buying Seagen for 43 BN and Arana for over 6Bn. Interesting they are splashing the cash on a Cancer treatment and Autoimmune treatment Company after jabbing half the World. I am sure there is no coincidence.

[marcusl2] 02/6/2023 22:19

Scancell moves closer to commercialising cancer immunotherapy treatment

HTTPS://www.voxmarkets.co.uk/articles/scancell-moves-closer-to-commercialising-cancer-immunotherapy-treatment--36e46fb/

wtp

[j777j] 02/6/2023 16:24

Multiple possible cancer cures.Should be back to the 20's in no time

[marcusl2] 02/6/2023 13:52

21 February 2023

Moditope shows early signs of efficacy The Phase I/II Modi-1 study (ModiFY) is a two stage trial. The initial dose escalation and safety phase is followed by a number of specific patient cohorts that explore for signs of efficacy in triple negative breast cancer (TNBC), ovarian cancer, head & neck cancer, and renal cancer as both Modi-1 monotherapy and in combination with checkpoint inhibitors (CPI). A total of up to 138 patients across up to 20 UK sites will be treated, with 23 successfully vaccinated so far. Of these, 14 patients have reached the eight-week evaluation point, with no dose-limiting toxicities or safety concerns seen. Despite having failed at least one round of prior treatment and having progressive disease prior to study enrolment, one patient has a confirmed partial response and seven have stable disease.

Progressing into combination therapy With safety and tolerability confirmed, Modi-1 is progressing into further dose escalation as monotherapy and, importantly, initiating combination therapy with a CPI. It is data from these elements of the study that will provide multiple insights into how and where Modi-1 could be employed. The indications selected are all aggressive and difficult to treat cancers, with clear clinical needs. If the early efficacy signals seen in the first part of ModiFY are confirmed in the latter parts, this would effectively demonstrate Moditope’s mode of action and would further de-risk the programme in our rNPV model.

Raising our valuation to £300.1m, equivalent to 36.7p We explored Scancell’s investment case in detail in our recent February 2023 Outlook. Increasing the probability on Moditope to 12.5% (from 10%) sees our rNPV rise to £300.1m (from £269.6m), or 36.7p/share (30.5p fully diluted). The next 12 to 18 months should see several potential value inflection points, ranging from trial results to further commercial deals. Positive outcomes should boost investor sentiment materially.

HTTPS://www.trinitydelta.org/research-notes/modi-1-successful-in-first-part-of-phase-i-ii-trial/

[golcheja] 02/6/2023 11:03

High dose + CPI, now in progress + no safety issues reported = excellent update. In addition, results so far are encouraging. AllinAll, a start for what should be revealed next week.
As big mama says good RNS talks and the rest walks.

[bermudashorts] 02/6/2023 10:34

MarkingTime,

This from the ASCO abstract submission guidelines clarifies the matter :-

'To ensure the integrity of the review process, revisions to abstracts will not be accepted after the abstract submission deadline.'

As I said, it would have been useful if the RNS had clarified the date because often the word 'acceptance' is used when papers/abstracts/applications meet submission criteria and are accepted for review. For example FDA 'accepting' a new drug application means they accept it for review, it doesn't mean the drug is approved.

Anyway moving on, the abstract itself has already been published and discussed on lse about a week ago. We now need to wait and see what additional information/data appears on the poster. We'll get an RNS if Scancell consider that it's price sensitive or if Scancell decide to use it as an opportunity to update the market with additional new data/results not included on the poster.

[marcusl2] 02/6/2023 09:50

HTTPS://www.proactiveinvestors.co.uk/companies/news/1016782/scancell-updates-on-progress-ahead-of-asco-poster-presentation-1016782.html?viewSource=TwitterUK


HTTPS://www.investegate.co.uk/announcement/7556348

[marcusl2] 02/6/2023 09:48

Scancell makes two medical appointments
Sunday 29 November 2020
Company Scancell Holdings Plc
Appointee nameGillies O'Bryan-Tear and Robert Miller

(Dr Miller has an in-depth knowledge of protocol development, particularly in early phase studies, and his frequent input in medical affairs to support health authority applications and interactions)

[markingtime] 02/6/2023 09:36

The implication is that updates can be made (otherwise why specify that data is included up to the date of acceptance....rather than date of submission?). If they meant submission they would have said so.Whatever the case, though, there is a minimum of a further 9-10 weeks of data to update the market on next week. IMO we are certain to get an update in June before the world stops until September, so next week would be perfect.....with a further update 13 weeks on in early September.

[inanaco] 02/6/2023 09:17

An abstract is a short summary that comes at the beginning of an academic paper, dissertation, or report. It summarises the whole paper, including the purpose of the research, methods, findings and conclusions. It is usually only a paragraph or two in length.

[marcusl2] 02/6/2023 08:28

The poster, being presented by Dr Robert Miller, Medical Director, describes the protocol and presents the results after completion of the monotherapy dose-finding and provides an update on patients recruited into the monotherapy dose expansion cohorts and into the checkpoint inhibitor (CPI) combination dose-finding cohort .


Cohort 4 has been approved by the Safety Review Board and the first patient has been dosed.

.

[bermudashorts] 02/6/2023 08:25

MarkingTime

Possibly, but I don't think changes can be made to abstracts after the submission deadline so not sure it matters which one you choose

[markingtime] 02/6/2023 08:11

ASCO acceptance was surely end of March. Submission is clearly not acceptance.Furthermore, I'd suggest that next week would be a good time for a full update, if the company/Consilium consider that the ASCO presentation creates an outdated impression of the trial status.